TY - JOUR
T1 - Perivagal antagonist treatment in rats selectively blocks the reflex and afferent responses of vagal lung C fibers to intravenous agonists
AU - Lin, Yu Jung
AU - Lin, You Shuei
AU - Lai, Ching Jung
AU - Yuan, Zung Fan
AU - Ruan, Ting
AU - Kou, Yu Ru
PY - 2013/2/1
Y1 - 2013/2/1
N2 - The terminals of vagal lung C fibers (VLCFs) express various types of pharmacological receptors that are important to the elicitation of airway reflexes and the development of airway hypersensitivity. We investigated the blockade of the reflex and afferent responses of VLCFs to intravenous injections of agonists using perivagal treatment with antagonists (PAT) targeting the transient receptor potential vanilloid 1, P2X, and 5-HT3 receptors in anesthetized rats. Blockading these responses via perivagal capsaicin treatment (PCT), which blocks the neural conduction of C fibers, was also studied. We used capsaicin, α,β-methylene-ATP, and phenylbiguanide as the agonists, and capsazepine, iso-pyridoxalphosphate- 6-azophenyl-2=,5=- disulfonate, and tropisetron as the antagonists of transient receptor potential vanilloid 1, P2X, and 5-HT3 receptors, respectively. We found that each of the PATs abolished the VLCF-mediated reflex apnea evoked by the corresponding agonist, while having no effect on the response to other agonists. Perivagal vehicle treatment failed to produce any such blockade. These blockades had partially recovered at 3 h after removal of the PATs. In contrast, PCT abolished the reflex apneic response to all three agonists. Both PATs and PCT did not affect the myelinated afferentmediated apneic response to lung inflation. Consistently, our electrophysiological studies revealed that each of the PATs prevented the VLCF responses to the corresponding agonist, but not to any other agonist. PCT inevitably prevented the VLCF responses to all three agonists. Thus these PATs selectively blocked the stimulatory action of corresponding agonists on the VLCF terminals via mechanisms that are distinct from those of PCT. PAT may become a novel intervention for studying the pharmacological modulation of VLCFs.
AB - The terminals of vagal lung C fibers (VLCFs) express various types of pharmacological receptors that are important to the elicitation of airway reflexes and the development of airway hypersensitivity. We investigated the blockade of the reflex and afferent responses of VLCFs to intravenous injections of agonists using perivagal treatment with antagonists (PAT) targeting the transient receptor potential vanilloid 1, P2X, and 5-HT3 receptors in anesthetized rats. Blockading these responses via perivagal capsaicin treatment (PCT), which blocks the neural conduction of C fibers, was also studied. We used capsaicin, α,β-methylene-ATP, and phenylbiguanide as the agonists, and capsazepine, iso-pyridoxalphosphate- 6-azophenyl-2=,5=- disulfonate, and tropisetron as the antagonists of transient receptor potential vanilloid 1, P2X, and 5-HT3 receptors, respectively. We found that each of the PATs abolished the VLCF-mediated reflex apnea evoked by the corresponding agonist, while having no effect on the response to other agonists. Perivagal vehicle treatment failed to produce any such blockade. These blockades had partially recovered at 3 h after removal of the PATs. In contrast, PCT abolished the reflex apneic response to all three agonists. Both PATs and PCT did not affect the myelinated afferentmediated apneic response to lung inflation. Consistently, our electrophysiological studies revealed that each of the PATs prevented the VLCF responses to the corresponding agonist, but not to any other agonist. PCT inevitably prevented the VLCF responses to all three agonists. Thus these PATs selectively blocked the stimulatory action of corresponding agonists on the VLCF terminals via mechanisms that are distinct from those of PCT. PAT may become a novel intervention for studying the pharmacological modulation of VLCFs.
KW - 5-HT3 receptors
KW - Lung
KW - P2X receptors
KW - Perivagal antagonist treatment
KW - Reflex
KW - TRPV1
KW - Vagal C fibers
UR - http://www.scopus.com/inward/record.url?scp=84873468667&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873468667&partnerID=8YFLogxK
U2 - 10.1152/japplphysiol.00977.2012
DO - 10.1152/japplphysiol.00977.2012
M3 - Article
C2 - 23221955
AN - SCOPUS:84873468667
SN - 8750-7587
VL - 114
SP - 361
EP - 370
JO - Journal of Applied Physiology
JF - Journal of Applied Physiology
IS - 3
ER -